Cart
sales@molnova.com
MSAB
CAS No. 173436-66-3
MSAB( —— )
Catalog No. M22633 CAS No. 173436-66-3
MSAB is a selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin, promoting its degradation, and specifically downregulates Wnt/β-catenin target genes.MSAB act against Wnt/β-catenin signaling and identified as a selective inhibitor of Wnt/β-catenin signaling.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 38 | In Stock |
|
| 5MG | 60 | In Stock |
|
| 10MG | 110 | In Stock |
|
| 25MG | 222 | In Stock |
|
| 50MG | 335 | In Stock |
|
| 100MG | 507 | In Stock |
|
| 500MG | 1062 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMSAB
-
NoteResearch use only, not for human use.
-
Brief DescriptionMSAB is a selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin, promoting its degradation, and specifically downregulates Wnt/β-catenin target genes.MSAB act against Wnt/β-catenin signaling and identified as a selective inhibitor of Wnt/β-catenin signaling.
-
DescriptionMSAB is a selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin, promoting its degradation, and specifically downregulates Wnt/β-catenin target genes.MSAB act against Wnt/β-catenin signaling and identified as a selective inhibitor of Wnt/β-catenin signaling. MSAB shows potent anti-tumor effects selectively on Wnt-dependent cancer cells in vitro and in mouse cancer models. MSAB binds to β-catenin, promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. might represent an effective therapeutic strategy for cancers addicted to the Wnt/β-catenin signaling pathway.
-
In VitroMSAB (2-10 μM) selectively decreases cell viability of Wnt-dependent cells while showing little effect on Wnt-independent cells and normal human cells. MSAB (0.01-10 μM; 20 h) inhibits T-cell factor (TCF) luciferase reporter activity in HCT116 cells. MSAB (20 h) suppresses the Wnt3a-induced TOP-Luc activation and increases of active β-catenin levels in HEK293T cells. MSAB (0.5-10 μM; 20 h) decreases mRNA and protein levels of endogenous Wnt target genes in HCT116 cells. MSAB (5 μM; 16 h) induces degradation of β-catenin in a proteasome-dependent manner in HCT116 cells.
-
In VivoMSAB (10-20 mg/kg; i.p. daily for 2 weeks) inhibits tumor growth of Wnt-dependent cancer cells in mouse xenograft model. MSAB (10-20 mg/kg; i.p. twice daily for 2 weeks) inhibits tumor growth of MMTV-Wnt1 transgenic mice. Animal Model:Athymic nude mice (5-6 weeks) are injected HCT116, HT115, H23, or H460 cells Dosage:10, 20 mg/kg Administration:I.p. dailyfor 2 weeks Result:Reduced the size and weight of various types of Wnt-dependent HCT116, HT115, and H23 tumors.
-
Synonyms——
-
PathwayWnt/Notch/Hedgehog
-
TargetWnt/beta/catenin
-
RecptorWnt/β-catenin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number173436-66-3
-
Formula Weight305.35
-
Molecular FormulaC15H15NO4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (818.73 mM)
-
SMILESCOC(=O)c1cccc(NS(=O)(=O)c2ccc(C)cc2)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hwang SY, et, al. Direct Targeting of β-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/β-Catenin Signaling. Cell Rep. 2016 Jun 28;16(1):28-36.
molnova catalog
related products
-
WIC1
WIC1 is a potent Wnt inhibitor. WIC1 can be used in cancer research
-
WWL70
WWL70 is a selective alpha/beta hydrolase domain 6 inhibitors (IC50: 70 nM). WWL70 (10 μM, 1 h) treatment, 2-Arachidonoylglycerol is increased by 20% compared to untreated cells.
-
KY02111
KY02111 promotes differentiation of hPSCs to cardiomyocytes by inhibiting Wnt signaling.
